Approval · Notice of Compliance 23052 · 2019
LAPELGA: Notice of Compliance 23052
Issued December 27, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23052
- Date
- December 27, 2019
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Labelling updates
- Canadian reference product
- NEULASTA
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LAPELGA | Not yet assigned | — |
Medicinal ingredients
- PEGFILGRASTIM 6 MG per 0.6ML